Vor Bio (NASDAQ: VOR) announced it has dosed the first patient in UPSTREAM SjD, a global phase 3 trial testing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE